低负荷前哨淋巴结阳性早期乳腺癌患者腋窝处理策略

doi:10.3760/cma.j.issn.1004-4221.2018.06.016

Abstract
Figure/Table
References()
Related Citation (3)
Read Tracking
Download Tracking

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract

For patients with positive sentinel lymph nodes, axillary lymph node dissection (ALND) is the conventional treatment. However, ALND can cause seroma, the upper limb dysfunction, edema and alternative complications. Z0011, IBCSG 23-01 and AMAROS phase Ⅲ randomized controlled clinical trials recommend ALND after sentinel lymph node biopsy in N0 patients, which provides a novel option for axillary lymph node treatment, but also brings new challenges to the decision of adjuvant radiotherapy. In this paper, based upon these three clinical trials and latest literatures related to the risk of axillary lymph node metastasis and recurrence, the therapeutic strategies including surgery and adjuvant radiotherapy for patients with positive sentinel lymph nodes are reviewed and summarized.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Cao Lu
	Chen Jiayi

Key words： Early breast neoplasm/radiotherapy Positive sentinel lymph node Axillary lymph node

Received: 28 July 2017

Fund:

National Natural Science Foundation of China (81172504, 81673102 and 81602791);National Key Research and Development Program (2016YFC0105409);Youth Research Project of Shanghai Municipal Health and Family Planning Commission (20164Y0066)

Corresponding Authors: Chen Jiayi,Email:chenjiayi0188@aliyun.com

Cite this article:

Cao Lu,Chen Jiayi. Therapeutic strategies of axillary treatment for early breast cancer patients with positive sentinel lymph nodes[J]. Chinese Journal of Radiation Oncology, 2018, 27(6): 612-615.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.issn.1004-4221.2018.06.016 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2018/V27/I6/612

[1] Perou CM,Sørlie T,Eisen MB,et al. Molecular portraits of human breast tumours[J].Nature,2000,406(6797):747-752.DOI:10.1038/35021093.
[2] Goldhirsch A,Wood WC,Coates AS,et al. Strategies for subtypes—dealing with the diversity of breast cancer:highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011[J].Ann Oncol,2011,22(8):1736-1747.DOI:10.1093/annonc/mdr304.
[3] Goldhirsch A,Winer EP,Coates AS,et al. Personalizing the treatment of women with early breast cancer:highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013[J].Ann Oncol,2013,24(9):2206-2223.DOI:10.1093/annonc/mdt303.
[4] Lyman GH,Giuliano AE,Somerfield MR,et al. American society of clinical oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer[J].J Clin Oncol,2005,23(30):7703-7020.DOI:10.1200/JCO.2005.08.001.
[5] Rao R,Euhus D,Mayo HG,et al. Axillary node interventions in breast cancer:a systematic review[J].JAMA,2013,310(13):1385-1394.DOI:10.1001/jama.2013.277804.
[6] Yeoh EK,Denham JW,Davies SA,et al. Primary breast cancer complications of axillary management[J].Acta Radiol Oncol,1986,25(2):105-108.DOI:10.3109/02841868609136386.
[7] Lotze MT,Duncan MA,Gerber LH,et al. Early versus delayed shoulder motion following axillary dissection:a randomized prospective study[J].Ann Surg,1981,193(3):288-295.DOI:10.1097/00000658-198103000-00007.
[8] Ivens D,Hoe AL,Podd TJ,et al. Assessment of morbidity from complete axillary dissection[J].Br J Cancer,1992,66(1):136-138.DOI:10.1038/bjc.1992.230.
[9] Swedish Organised Service Screening Evaluation Group. Effect of mammographic service screening on stage at presentation of breast cancers in Sweden[J].Cancer,2007,109(11):2205-2212.DOI:10.1002/cncr.22671.
[10] Giuliano AE,Hunt KK,Ballman KV,et al. Axillary dissection vs. no axillary dissection in women with invasive breast cancer and sentinel node metastasis:a randomized clinical trial[J].JAMA,2011,305(6):569-575.DOI:10.1001/jama.2011.90.
[11] Galimberti V,Cole BF,Zurrida S,et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01):a phase 3 randomised controlled trial[J].Lancet Oncol,2013,14(4):297-305.DOI:10.1016/S1470-2045(13)70035-4.
[12] Donker M,Van Tienhoven G,Straver ME,et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS):a randomised,multicentre,open-label,phase 3 non-inferiority trial[J].Lancet Oncol,2014,15(12):1303-1310.DOI:10.1016/S1470-2045(14)70460-7.
[13] Gradishar WJ,Anderson BO,Balassanian R,et al. NCCN guidelines insights:breast cancer,version 1.2017[J].J Natl Compr Cancer Netw,2017,15(4):433-451.DOI:10.6004/jnccn.2017.0044.
[14] Gnant M,Harbeck N,Thomssen C.St. Gallen/Vienna 2017:a brief summary of the consensus discussion about escalation and De-escalation of primary breast cancer treatment[J].Breast Care,2017,12(2):102-107.
[15] Giuliano AE,Ballman K,McCall L,et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases:Long-term Follow-up from the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 randomized trial[J].Ann Surg,2016,264(3):413-420.DOI:10.1097/SLA.0000000000001863.
[16] Jagsi R,Chadha M,Moni J,et al. Radiation field design in the ACOSOG Z0011(Alliance) Trial[J].J Clin Oncol,2014,32(32):3600-3606.DOI:10.1200/JCO.2014.56.5838.
[17] Haffty BG,Hunt KK,Harris JR,et al. Positive sentinel nodes without axillary dissection:implications for the radiation oncologist[J].J Clin Oncol,2011,29(34):4479-4481.DOI:10.1200/JCO.2011.36.1667.
[18] 朱传营,蔡钢,胡伟刚,等.乳房保留术后野中野正向调强全乳房照射的腋窝淋巴结剂量学研究[J].中华放射肿瘤学杂志,2014,23(6):500-504.DOI:10.3760/cma.j.issn.1004-4221.2014.06.011.
Zhu CY,Cas G,Hu WG,et al. Radiation doses to axillary lymph nodes in patients with early breast cancer receiving field-in-field forward-planned intensity-modulated radiotherapy for whole breast irradiation after breast-conserving surgery[J].Chin J Radiat Oncol,2014,23(6):500-504.DOI:10.3760/cma.j.issn.1004-4221.2014.06.011.
[19] Reznik J,Cicchetti MG,Degaspe B,et al. Analysis of axillary coverage during tangential radiation therapy to the breast[J].Int J Radiat Oncol Biol Phys,2005,61(1):163-168.DOI:10.1016/j.ijrobp.2004.04.065.
[20] Reed DR,Lindsley SK,Mann GN,et al. Axillary lymph node dose with tangential breast irradiation[J].Int J Radiat Oncol Biol Phys,2005,61(2):358-364.DOI:10.1016/j.ijrobp.2004.06.006.
[21] Surmann K,Van Der Leer J,Branje T,et al. Elective breast radiotherapy including level I and Ⅱ lymph nodes:a planning study with the humeral head as planning risk volume[J].Radiat Oncol,2017,12:22.DOI:10.1186/s13014-016-0759-7.
[22] Van Zee KJ,Manasseh DM,Bevilacqua JL,et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy[J].Ann Surg Oncol,2003,10(10):1140-1051.DOI:10.1245/ASO.2003.03.015.
[23] Alran S,De Rycke Y,Fourchotte V,et al. Validation and limitations of use of a breast cancer nomogram predicting the likelihood of non-sentinel node involvement after positive sentinel node biopsy[J].Ann Surg Oncol,2007,14(8):2195-2201.
[24] Sasada T,Murakami S,Kataoka T,et al. Memorial Sloan-Kettering Cancer Center Nomogram to predict the risk of non-sentinel lymph node metastasis in Japanese breast cancer patients[J].Surg Today,2012,42(3):245-249.DOI:10.1007/s00595-011-0088-2.
[25] Katz A,Smith BL,Golshan M,et al. Nomogram for the prediction of having four or more involved nodes for sentinel lymph node-positive breast cancer[J].J Clin Oncol,2008,26(13):2093-2098.DOI:10.1200/JCO.2007.11.9479.
[26] Senkus E,Kyriakides S,Ohno S,et al. Primary breast cancer:ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2015,26 Suppl 5:v8-30.DOI:10.1093/annonc/mdv298.
[27] Whelan TJ,Olivotto IA,Parulekar WR,et al. Regional nodal irradiation in early-stage breast cancer[J].N Engl J Med,2015,373(4):307-316.DOI:10.1056/NEJMoa1415340.
[28] Poortmans PM,Collette S,Kirkove C,et al. Internal mammary and medial supraclavicular irradiation in breast cancer[J].N Engl J Med,2015,373(4):317-27.DOI:10.1056/NEJMoa1415369.
[29] Thorsen LB,Offersen BV,Danø H,et al. DBCG-IMN:a population-based cohort study on the effect of internal mammary node irradiation in early node-positive breast cancer[J].J Clin Oncol,2016,34(4):314-320.DOI:10.1200/JCO.2015.63.6456.